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studied toward potential beneﬁcial application of statins.
The present talk will give an overview of animal models of
infection with respect to effects of statin treatment.
doi:10.1016/j.ijid.2008.05.0566 13th Internat
f cholera patients as well as in the severity of the disease
as been observed. Globally, also there has been a substan-
ial increase in the incidence of cholera and in the number
f outbreaks of cholera.
oi:10.1016/j.ijid.2008.05.053
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otavirus vaccines currently licensed in more than 90 coun-
ries hold the promise of preventing more than 600,000
iarrhea deaths and many hospitalizations and doctor vis-
ts worldwide. The positive impact of vaccination programs
s just becoming evident in US and middle income countries
f Latin America and as yet, no major danger signs such
s intussusception have clouded the horizon. At the same
ime, the efﬁcacy of these new rotavirus vaccines has not
een demonstrated in poor developing countries and some
minous signs are appearing that are cause for concern. The
mmune response to the GSK vaccine in infants in S. Africa
nd Bangladesh has been substantially less than that mea-
ured in studies in Latin America, the US and Finland and
his difference may be reﬂected in lower efﬁcacy. Trials now
ngoing should determine the efﬁcacy in two populations in
ub-Saharan Africa. The reasons for this impaired immune
esponse are numerous - high titers of maternal antibody,
reast feeding practices, and interfering gut ﬂora, micronu-
rient deﬁciency- to name a few and ways to address these
ssues will be key to either improving these vaccines or to
ejecting them should the results of ongoing ﬁeld trials prove
isappointing. To date, no serious discussion has been given
o the level of efﬁcacy that the international community
ould deem acceptable for rotavirus vaccines to receive
global recommendation from WHO. Research is needed
oday to identify the cause of the low immune responses
nd to identify strategies to improve this problem. Insur-
nce policies to consider new vaccines should be considered
s well so that alternative vaccine candidates are in the
ings should they be needed.
oi:10.1016/j.ijid.2008.05.054
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ortality from sepsis is a leading cause of death world-
ide. Clinical observational studies of the effect of statins
n reducing the morbidity and mortality of sepsis suggest a
revention, and possible treatment, effect. Effects at the
ranscriptional level lead to the reduced expression of var-
ous inﬂammatory mediators by leukocytes and endotheliall Congress on Infectious Diseases Abstracts (Invited Papers)
ells. Heme oxygenase induction has anti-oxidant, anti-
nﬂammatory, and cytoprotective effects. Direct blockade
lters leukocyte-endothelial cell interaction, while reduced
xpression of MHC-II affects T-cell function. That statins do
ot target individual inﬂammatory mediators, but possibly
educe the overall magnitude of the systemic response, may
rove an important distinguishing feature modulating the
ost response to septic insults.
oi:10.1016/j.ijid.2008.05.055
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tatins, are effective lipid lowering agents used extensively
n medical practice. Recent statin studies have extended
tatin therapy to the acute manifestations of cardiovas-
ular disease and have suggested cholesterol independent
herapeutic beneﬁts, termed ‘‘pleiotropic’’ effects, which
ave added a wide scope of potential targets for statin
herapy. Since the approval for clinical use in humans of
ovastatin as the ﬁrst statin several statins have become
ommercially available including pravastatin, simvastatin,
uvastatin, atorvastatin, cerivastatin (withdrawn in 2001),
itavastatin and rosuvastatin. While all these statins share
MG-CoA reductase inhibition as common mechanism of
ction, they differ in absorption, afﬁnity, binding, solubil-
ty and excretion. Apart from causing variations in efﬁcacy
f cholesterol lowering between the agents, differences in
hese pharmacologic properties might also be relevant with
espect to so called ‘‘pleiotropic’’ effects of statins. These
‘pleiotropic’’ effects include anti-inﬂammatory and antiox-
dative properties, improvement of endothelial function and
ncreased nitric oxide bioavailability and thus might con-
ribute to the beneﬁt observed with statin therapy. Notably,
hese important immunomodulatory effects of statins have
een demonstrated to be independent of lipid lowering and
ppear to be mediated via interference with the synthesis
f mevalonate metabolites (nonsteroidal isoprenoid prod-
cts). In addition, mechanisms for anti-inﬂammatory actions
f statins have been revealed that are not related to the
soprenoid metabolism. For instance, it has been identiﬁed
hat some statins act as direct antagonists of LFA-1 due to
heir capacity to bind to the regulatory site in the LFA-1
-domain. Several animal models of infection ranging from
acterial, and fungal to viral causative agents have been
